Identifying and treating COPD in cardiac patients

Chest

Volumn 144, Issue 3, 2013, Pages 723-726

  Nozzoli, Carlo ^a   Beghè, Bianca ^b   Boschetto, Piera ^c   Fabbri, Leonardo M ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ROFLUMILAST;

ACUTE HEART INFARCTION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HEART DEATH; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SLEEP DISORDERED BREATHING; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

EID: 84884313840     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0915     Document Type: Editorial

References (30)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 ; 187 (4): 347-365.
2. Steg PG, James SK, Atar D, et al ; Task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 ; 33 (20): 2569-2619.
3. Boschetto P, Beghé B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012 ; 17 (3): 422-431.
4. Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013 ; 143 (3): 798-807.
5. Lee HM, Lee J, Lee K, Luo Y, Sin DD, Wong ND. Relation between COPD severity and global cardiovascular risk in US adults. Chest. 2012 ; 142 (5): 1118-1125.
6. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006 ; 27 (1): 188-207.
7. Hadi HA, Zubaid M, Al Mahmeed W, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol. 2010 ; 33 (4): 228-235.
8. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010 ; 106 (3): 305-309.
9. Hawkins NM, Huang Z, Pieper KS, et al ; Valsartan in Acute Myocardial Infarction Trial Investigators. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009 ; 11 (3): 292-298.
10. Soriano JB. Prevalence, determinants and under-diagnosis of airfl ow limitation in subjects with ischaemic heart dis ease in Europe [A2410]. Abstract presented at: American Thoracic Society International Conference; May 17-22, 2013; Philadelphia, PA.
11. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airfl ow limitation in patients with cardiovascular disease. Chest. 2010 ; 137 (2): 333-340.
12. Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure in the elderly. Int J Cardiol. 2008 ; 125 (2): 209-215.
13. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J. 2010 ; 160 (1): 95-101.
14. Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013 ; 144 (3): 750-757.
15. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Med Clin North Am. 2012 ; 96 (4): 789-809.
16. Wolff JL, Starfi eld B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002 ; 162 (20): 2269-2276.
17. Beller GA. Are you ever too old to be risk stratifi ed? J Am Coll Cardiol. 1992 ; 19 (7): 1399-1401.
18. Balzi D, Barchielli A, Buiatti E, et al ; AMI-Florence Working Group. Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. Am Heart J. 2006 ; 151 (5): 1094-1100.
19. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT. 25 year trends in fi rst time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012 ; 344 : e356.
20. Coles AH, Fisher KA, Darling C, et al. Recent trends in postdischarge mortality among patients with an initial acute myocardial infarction. Am J Cardiol. 2012 ; 110 (8): 1073-1077.
21. Nauta ST, Deckers JW, van Domburg RT, Akkerhuis KM. Sex-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008: equal benefi t for women and men. Circulation. 2012 ; 126 (18): 2184-2189.
22. Norhammar A, Lindbäck J, Rydén L, Wallentin L, Stenestrand U ; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short-and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 2007 ; 93 (12): 1577-1583.
23. Lee CH, Khoo SM, Chan MY, et al. Severe obstructive sleep apnea and outcomes following myocardial infarction. J Clin Sleep Med. 2011 ; 7 (6): 616-621.
24. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving rofl umilast for the treatment of COPD. Chest. 2013 ; 144 (3): 758-765.
25. De Martinis M, Franceschi C, Monti D, Ginaldi L. Infl ammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol. 2006 ; 80 (3): 219-227.
26. Decramer M, Jannsen W. Chronic obstructive pulmonary disease and comorbidities. The Lancet Respiratory Medicine. 2013 ; 1 (1): 73-83.
27. Wouters EF, Bredenbröker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor rofl umilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 ; 97 (9): E1720-E1725.
28. Luppi F, Franco F, Beghé B, Fabbri LM. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008 ; 5 (8): 848-856.
29. Vanfl eteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic infl ammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 ; 187 (7): 728-735.
30. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol Eur Respir J. 2013 ; 41 (5): 1017 - 1022